Protection and mechanisms of hydroxysafflor yellow A on experimental myocardial infarction in rats

Chinese Traditional and Herbal Drugs

Volumn 38, Issue 12, 2007, Pages 1853-1856

  Wang, Tian ^a   Fu, Feng Hua ^a   Han, Bing ^a   Zhu, Mei ^a   Li, Gui Sheng ^a   Liu, Ke ^a  

^a YANTAI UNIVERSITY   (China)

Author keywords

Ang II; Hydroxysafflor yellow A (HSYA); Myocardial infarction; TXB2

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANGIOTENSIN II; CARDIOVASCULAR AGENT; CREATINE KINASE MB; HYDROXYSAFFLOR YELLOW A EXTRACT; LACTATE DEHYDROGENASE; MUELLERIAN INHIBITING FACTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLANT EXTRACT; THROMBOXANE B2; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MECHANISM; HEART PROTECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; NONHUMAN; PROSTAGLANDIN BLOOD LEVEL; RAT;

EID: 37849030812     PISSN: 02532670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Romano C, Price M, Bai H Y, et al. Neuroprotectants in Honghua: glucose attenuates retinal ischemic damage [J]. Invest Ophthalmol Vis Sci, 1993, 34: 72-80.
2. Zhu H B, Wang Z H, Ma C J, et al. Neuroprotective effects of hydroxysafflor yellow A: in vivo and in vitro studies [J]. Planta Med, 2003, 69: 429-433.
3. Zhu H B, Zhang L, Wang Z H, et al. Therapeutic effects of hydroxysafflor yellow A on focal cerebral ischemic injury in rats and its primary mechanisms [J]. J Asian Nat Prod Res, 2005, 7: 607-613.
4. Lou H, He Q, Wu H, et al. Experimental research on total flavone from Elsholtzia blanda against Xiongbi symptom [J]. J Chin Med Mater, 2003, 26: 878-880.
5. Ling H Y, Lou Y J, Lou H G, et al. Protective effect of total flavones from Elsholtzia blanda (TFEB) on myocardial ischemia induced by coronary occlusion in canines [J]. J Ethnopharmacol, 2004, 94: 101-107.
6. Moncada S, Palmer R M, Higgs E A, et al. Nitric oxide: physiology, pathophysiology, and pharmacology [J]. Pharmacol Rev, 1991, 43(2): 109-142.
7. Davis K L, Martin E, Turko I V, et al. Novel effects of nitric oxide [J]. Annu Rev Pharmacol Toxicol, 2001, 41: 203-236.
8. Grosser T, Fries S, Fitzgerald G A, et al. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities [J]. J Clin Invest, 2006, 116(1): 4-15.
9. Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis [J]. Cell Metab, 2005, 2(3): 201-207.
10. Suzuki H, Frank G D, Utsunomiya H, et al. Current understanding of the mechanism and role of ROS in angiotensin II signal transduction [J]. Curr Pharm Biotechnol, 2006, 7(2): 81-86.
11. Kajstura J, Cigola E, Malhotra A, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro [J]. J Mol Cell Cardiol, 1997, 29(3): 859-870.